Priority Review vs Standard Review: The FDA Clock Explained

You read an NDA filing press release. It says “Priority Review granted.” The stock jumps 5%. What just happened?

Priority Review is an FDA designation that shortens the review clock from 10 months to 6 months. That’s it. It doesn’t mean the drug is better, doesn’t mean approval is guaranteed, and doesn’t change the scientific standard for approval. It means the FDA moves faster. For investors, that changes the catalyst calendar and the timeline for your trade.

The Solution

When a company files an NDA or BLA, the FDA assigns either Priority Review (6-month target) or Standard Review (10-month target). The designation tells you when the PDUFA date lands and offers a read on FDA sentiment. Learn the difference, check the designation in every filing press release, and map it to your trade timeline.

Step 1: Know the timelines

Priority Review: the FDA’s goal is to act within 6 months of accepting the application.

Standard Review: the FDA’s goal is to act within 10 months of acceptance.

The clock starts when the FDA accepts the application, typically 60 days after submission. The PDUFA date is the target action date at the end of that clock. A Priority Review PDUFA lands roughly 4 months earlier than a Standard Review PDUFA for the same filing date.

Real example: Cogent Biosciences (COGT) filed its NDA for bezuclastinib in non-advanced systemic mastocytosis based on the SUMMIT registrational trial. The FDA accepted it with Priority Review and a PDUFA date of December 30, 2026. If it had received Standard Review, the PDUFA would land closer to mid-2027. Four months of difference on the catalyst calendar.

Step 2: Understand the criteria

Priority Review goes to drugs that treat a serious condition AND, if approved, would provide a significant improvement in safety or effectiveness compared to existing treatments. The FDA’s official criteria define “significant improvement” as:

• Evidence of increased effectiveness in treatment, prevention, or diagnosis
• Elimination or substantial reduction of a treatment-limiting drug reaction
• Documented enhancement of patient compliance expected to improve serious outcomes
• Evidence of safety and effectiveness in a new subpopulation

Most drugs get Standard Review. Priority Review is the exception, not the default.

Step 3: Don’t confuse it with other designations

This is where investors get tried up. Priority Review is one of four FDA expedited programs, and they’re commonly conflated:

Designation	What it does	Timeline impact
Fast Track	Rolling submission of data; more frequent FDA communication	Speeds development, not review
Breakthrough Therapy	All Fast Track benefits plus intensive FDA guidance from Phase 1 onward	Speeds development, not review
Accelerated Approval	Approval based on a surrogate endpoint instead of clinical outcome	Changes the approval standard, not the timeline
Priority Review	Shorter FDA review clock	6 months vs 10 months

A drug can have multiple designations simultaneously. Cogent’s bezuclastinib GIST NDA has both Breakthrough Therapy and Priority Review. Breakthrough Therapy got Cogent more FDA meetings during development; Priority Review shortened the review clock. They serve different purposes.

The critical distinction: Fast Track and Breakthrough Therapy speed up drug development. Priority Review speeds up FDA review. Accelerated Approval changes what the FDA accepts as proof. For more on that last one, see our guide to accelerated approval.

Step 4: Check the designation in the filing press release

When a company announces NDA or BLA submission, the press release states the review designation. If it says “Priority Review,” mark your calendar for a PDUFA roughly 6 months out. If it says “Standard Review” or is silent on the designation, expect roughly 10 months.

Real example: Gilead Sciences (GILD) filed its NDA for bictegravir + lenacapavir (BIC/LEN) for HIV treatment. The FDA granted Priority Review with a PDUFA date of August 27, 2026. The BIC/LEN weekly HIV analysis covers the investment thesis in detail, but the point here is simple: Priority Review put this catalyst on a 6-month clock, not 10.

For supplemental applications, the same timelines apply. An sNDA or sBLA can receive Priority Review (6 months) or Standard Review (10 months). See our guide to sBLA and sNDA review timelines for the details on supplemental filings.

Step 5: Factor in Priority Review Vouchers

There’s a twist. Companies that win approval for certain rare pediatric or tropical disease drugs receive a Priority Review Voucher (PRV): a transferable coupon that converts any Standard Review into Priority Review. The voucher holder can use it on their own drug or sell it to another company.

PRVs have sold for $67M to $180M. For small-cap biotechs, a PRV sale can exceed the company’s entire quarterly revenue. Rocket Pharmaceuticals (RCKT) sold a Rare Pediatric Disease PRV for $180M in April 2026, non-dilutive capital that extended their cash runway to Q2 2028.

When you see Priority Review on a filing, check whether the company earned it on merit or bought a voucher. Both result in a 6-month clock, but the voucher route tells you nothing about FDA enthusiasm for the drug itself. See our Priority Review Voucher guide for the full mechanics.

Common mistakes

Treating Priority Review as an approval signal. It’s not. The FDA’s own guidance states: “Designation of a drug as ‘Priority’ does not alter the scientific/medical standard for approval or the quality of evidence necessary.” A Priority Review drug can still get a Complete Response Letter. The 37% CRL base rate (2018-2022 PDUFA cycles) applies to Priority Review applications too.

Ignoring the filing date. A Priority Review PDUFA is 6 months from FDA acceptance, not from the company’s announcement. Check the FDA acceptance date, not the press release date.

Confusing Priority Review with Breakthrough Therapy. Breakthrough Therapy means intensive FDA hand-holding during development. Priority Review means a shorter review clock. A drug can have Breakthrough Therapy and Standard Review. Don’t assume one implies the other.

Final checklist

• Find the review designation in the NDA/BLA filing press release
• Priority Review means PDUFA in roughly 6 months; Standard Review means roughly 10 months
• Check whether the designation was earned or bought via a PRV
• Don’t confuse Priority Review with Breakthrough Therapy, Fast Track, or Accelerated Approval
• Track the PDUFA date on the FDA calendar and mark it 2 weeks before the deadline
• Remember: 37% of applications get a CRL regardless of review type

The FDA doesn’t care about your feelings. It cares about the calendar. Priority Review shortens that calendar by 4 months: useful for planning, but not a guarantee of anything. For the full PDUFA timeline mechanics, see our PDUFA date guide and the BLA vs NDA application types explainer.